Alta Partners
VC Fund
San Francisco, United States
Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.
- Total investments:
- 174
- Last investment:
- Lead investor:
- 23%
- Fund size:
- $275M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Alta Partners invests in
Stages Alta Partners invests in
Countries Alta Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6M–$52M
- Series B
- $16M–$93M
- Series C
- $10M–$109M
Investment Focus
Industry
- Biotechnology 65 (37%)
- Health Care 54 (31%)
- Medical 33 (19%)
- Therapeutics 26 (15%)
- Pharmaceutical 22 (13%)
Stage
- Series B 43 (25%)
- Series A 32 (18%)
- Series C 29 (17%)
- Series D 18 (10%)
- Funding Round 18 (10%)
Country
- United States 86 (49%)
- United Kingdom 2 (1%)
- China 1 (1%)
- Spain 1 (1%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dan Janney
Managing Director
|
Managing Director | Total investments: 14 | Find email | |
Peter Hudson
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
|
Alison de Bord
Director
|
Director | Total investments: 1 | Find email | |
Bob More
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
Edward Penhoet
Director
|
Director | Total investments: 6 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Harbor Health
|
Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas. | $130M / Series B / Sep 09, 2025 | |
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | $92M / Series C / Jan 15, 2025 | |
|
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | $82M / Venture - Series Unknown / Oct 22, 2024 | |
|
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | Series C / Oct 22, 2024 | |
EGenesis
|
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M / Series D / Sep 04, 2024 | |
Progentos Therapeutics
|
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms. | $65M / Series A / May 14, 2024 | |
Transcarent
|
Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care. | $126M / Series D / May 02, 2024 | |
Edgewood Oncology
|
Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs. | $20M / Series A / Mar 25, 2024 | |
|
Harbor Health
|
Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas. | $95.5M / Series A / Jan 11, 2024 | |
Lassen Therapeutics
|
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis, and blocking its activity has the potential to be moreeffective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. | $85M / Series B / Dec 19, 2023 | |
| See all 174 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alta Partners invest in?
Alta Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 174 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alta Partners's check size?
Alta Partners typically joins rounds of $6M–$52M at Series A, $16M–$93M at Series B and $10M–$109M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alta Partners participates in.
How do I contact Alta Partners?
Public channels for Alta Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alta Partners?
The team at Alta Partners includes Dan Janney (Managing Director), Peter Hudson (Managing Director) and Alison de Bord (Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
